![Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.](https://oncodaily.com/pub/uploads/2023/09/photo_2023-09-17_23-40-34-1-e1695106124500.jpg)
Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.
Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, recently shared a post by The Lancet Oncology on X/Twitter, adding:
“Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed. FOLFOX plus regorafenib and nivolumab for advanced EG cancer. ORR 76% and 6-month PFS 71%. Nice work, Sam Cytryn and team!”
Quoting The Lancet Oncology’s post:
“NOW OF: A US single-arm, single-center, phase 2 trial assesses the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma.”
For the article click here.
Source: Ryan Moy/Twitter and The Lancet Oncology/Twitter